• Je něco špatně v tomto záznamu ?

Distinct modulation of telomere length in two T-lymphoblastic leukemia cell lines by cytotoxic nucleoside phosphonates PMEG and PMEDAP

M. Hájek, V. Cvilink, I. Votruba, A. Holý, H. Mertlíková-Kaiserová,

. 2010 ; 643 (1) : 6-12. [pub] 20100622

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12026285

We have previously shown that PMEG diphosphate (PMEGpp) and PMEDAP diphosphate (PMEDAPpp) inhibit the enzymatic activity of human telomerase in a cell-free assay. Here, we investigated the ability of PMEG and PMEDAP to induce telomere shortening and telomerase inhibition at both transcriptional and activity level in T-lymphoblastic leukemia cells CCRF-CEM and MOLT-4. At defined time points (3days and 9weeks), the telomerase activity and relative levels of hTERT and c-myc mRNA were determined using real-time RT-PCR. Telomere length was measured by the flow-FISH method. Both PMEDAP and PMEG induced telomere shortening in CCRF-CEM cells after 9weeks of exposure by 50% and 20%, respectively, without major impairment of telomerase activity. The effect of the tested compounds on telomere length in MOLT-4 cells was the opposite, with telomere elongation by 50% and 40% after 9-week treatment with PMEDAP and PMEG, respectively. At this time point, telomerase activity in MOLT-4 cells appeared to be slightly higher than that of CCRF-CEM cells, nevertheless no correlation between telomerase activity and telomere length was found. Both compounds down-regulated the expression of hTERT and c-myc mRNA in CCRF-CEM and MOLT-4 cells at 72h in a concentration-dependent manner while prolonged exposure to PMEG or PMEDAP for 9weeks had weaker effects. In conclusion, PMEDAP and PMEG are able to modulate telomere length in leukemic cells and this effect is cell-type specific. It is neither due to direct telomerase inhibition nor impairment of hTERT expression and it is likely to be telomerase-independent.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12026285
003      
CZ-PrNML
005      
20121207101606.0
007      
ta
008      
120817e20100622ne f 000 0#eng||
009      
AR
024    7_
$a 10.1016/j.ejphar.2010.06.006 $2 doi
035    __
$a (PubMed)20599933
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Hájek, Miroslav $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic.
245    10
$a Distinct modulation of telomere length in two T-lymphoblastic leukemia cell lines by cytotoxic nucleoside phosphonates PMEG and PMEDAP / $c M. Hájek, V. Cvilink, I. Votruba, A. Holý, H. Mertlíková-Kaiserová,
520    9_
$a We have previously shown that PMEG diphosphate (PMEGpp) and PMEDAP diphosphate (PMEDAPpp) inhibit the enzymatic activity of human telomerase in a cell-free assay. Here, we investigated the ability of PMEG and PMEDAP to induce telomere shortening and telomerase inhibition at both transcriptional and activity level in T-lymphoblastic leukemia cells CCRF-CEM and MOLT-4. At defined time points (3days and 9weeks), the telomerase activity and relative levels of hTERT and c-myc mRNA were determined using real-time RT-PCR. Telomere length was measured by the flow-FISH method. Both PMEDAP and PMEG induced telomere shortening in CCRF-CEM cells after 9weeks of exposure by 50% and 20%, respectively, without major impairment of telomerase activity. The effect of the tested compounds on telomere length in MOLT-4 cells was the opposite, with telomere elongation by 50% and 40% after 9-week treatment with PMEDAP and PMEG, respectively. At this time point, telomerase activity in MOLT-4 cells appeared to be slightly higher than that of CCRF-CEM cells, nevertheless no correlation between telomerase activity and telomere length was found. Both compounds down-regulated the expression of hTERT and c-myc mRNA in CCRF-CEM and MOLT-4 cells at 72h in a concentration-dependent manner while prolonged exposure to PMEG or PMEDAP for 9weeks had weaker effects. In conclusion, PMEDAP and PMEG are able to modulate telomere length in leukemic cells and this effect is cell-type specific. It is neither due to direct telomerase inhibition nor impairment of hTERT expression and it is likely to be telomerase-independent.
650    _2
$a adenin $x analogy a deriváty $x farmakologie $7 D000225
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a buněčné kultury $7 D018929
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a elektroforéza v polyakrylamidovém gelu $7 D004591
650    _2
$a guanin $x analogy a deriváty $x farmakologie $7 D006147
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a organofosforové sloučeniny $x farmakologie $7 D009943
650    _2
$a protoonkogenní proteiny c-myc $x biosyntéza $7 D016271
650    _2
$a RNA $x metabolismus $7 D012313
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a telomerasa $x antagonisté a inhibitory $x biosyntéza $7 D019098
650    _2
$a telomery $x účinky léků $7 D016615
650    _2
$a časové faktory $7 D013997
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cvilink, Viktor
700    1_
$a Votruba, Ivan
700    1_
$a Holý, Antonín
700    1_
$a Mertlíková-Kaiserová, Helena
773    0_
$w MED00001641 $t European journal of pharmacology $x 1879-0712 $g Roč. 643, č. 1 (20100622), s. 6-12
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20599933 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120817 $b ABA008
991    __
$a 20121207101640 $b ABA008
999    __
$a ok $b bmc $g 948327 $s 783631
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 643 $c 1 $d 6-12 $e 20100622 $i 1879-0712 $m European journal of pharmacology $n Eur J Pharmacol $x MED00001641
LZP    __
$a Pubmed-20120817/10/04

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...